Editorial: inflammation, disease-modifying antirheumatic drugs, lipids, and cardiovascular risk in rheumatoid arthritis
- PMID: 25331004
- DOI: 10.1002/art.38925
Editorial: inflammation, disease-modifying antirheumatic drugs, lipids, and cardiovascular risk in rheumatoid arthritis
Comment on
-
An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy.Arthritis Rheumatol. 2015 Feb;67(2):372-80. doi: 10.1002/art.38920. Arthritis Rheumatol. 2015. PMID: 25332171
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
